Literature DB >> 11713237

Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts.

V Parikka1, P Lehenkari, M L Sassi, J Halleen, J Risteli, P Härkönen, H K Väänänen.   

Abstract

Decreased E2 levels after menopause cause bone loss through increased penetrative resorption. The reversal effect of E2 substitution therapy is well documented in vivo, although the detailed mechanism of action is not fully understood. To study the effects of E2 on bone resorption, we developed a novel in vitro bone resorption assay in which degradation of inorganic and organic matrix could be measured separately. E2 treatment significantly decreased the depth of resorption pits, although the area resorbed was not changed. Electron microscopy further revealed that the resorption pits were filled with nondegraded collagen, suggesting that E2 disturbed the organic matrix degradation. Two major groups of proteinases, matrix metalloproteinases (MMPs) and cysteine proteinases, have been suggested to participate in organic matrix degradation by osteoclasts. We show here that MMP-9 released a cross-linked carboxyl-terminal telopeptide of type I collagen from bone collagen, and cathepsin K released another C-terminal fragment, the C-terminal cross-linked peptide of type I collagen. E2 significantly inhibited the release of the C-terminal cross-linked peptide of type I collagen into the culture medium without affecting the release of cross-linked carboxyl-terminal telopeptide of type I collagen in osteoclast cultures. These results suggest that organic matrix degradation is initiated by MMPs and continued by cysteine proteases; the latter event is regulated by E2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713237     DOI: 10.1210/endo.142.12.8533

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  24 in total

1.  Interventional value of total flavonoids from Rhizoma Drynariae on Cathepsin K, a potential target of osteoporosis.

Authors:  Xiao-Lin Shi; Kang Liu; Lian-Guo Wu
Journal:  Chin J Integr Med       Date:  2011-07-03       Impact factor: 1.978

2.  Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases.

Authors:  Lingxin Zhu; Yi Tang; Xiao-Yan Li; Evan T Keller; Jingwen Yang; Jung-Sun Cho; Tamar Y Feinberg; Stephen J Weiss
Journal:  Sci Transl Med       Date:  2020-02-05       Impact factor: 17.956

3.  Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo.

Authors:  Kumar Pandya; Hyung-Suk Kim; Oliver Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-26       Impact factor: 11.205

4.  Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β.

Authors:  Polakit Teekakirikul; Seda Eminaga; Okan Toka; Ronny Alcalai; Libin Wang; Hiroko Wakimoto; Matthew Nayor; Tetsuo Konno; Joshua M Gorham; Cordula M Wolf; Jae B Kim; Joachim P Schmitt; Jefferey D Molkentin; Russell A Norris; Andrew M Tager; Stanley R Hoffman; Roger R Markwald; Christine E Seidman; Jonathan G Seidman
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

5.  A crucial role for thiol antioxidants in estrogen-deficiency bone loss.

Authors:  Jenny M Lean; Julie T Davies; Karen Fuller; Christopher J Jagger; Barrie Kirstein; Geoffrey A Partington; Zoë L Urry; Timothy J Chambers
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

6.  The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover.

Authors:  Anne-Christine Bay-Jensen; Nadine C B Tabassi; Lene V Sondergaard; Thomas L Andersen; Frederik Dagnaes-Hansen; Patrick Garnero; Moustapha Kassem; Jean-Marie Delaissé
Journal:  Arthritis Res Ther       Date:  2009       Impact factor: 5.156

7.  Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.

Authors:  Anita V Neutzsky-Wulff; Mette G Sørensen; Dino Kocijancic; Diana J Leeming; Morten H Dziegiel; Morten A Karsdal; Kim Henriksen
Journal:  BMC Musculoskelet Disord       Date:  2010-06-01       Impact factor: 2.362

8.  Immunohistochemical detection of estrogen receptor beta in alveolar bone cells of estradiol-treated female rats: possible direct action of estrogen on osteoclast life span.

Authors:  Mady Crusodé de Souza; Mady Cruzoé-Souza; Estela Sasso-Cerri; Paulo S Cerri
Journal:  J Anat       Date:  2009-12       Impact factor: 2.610

Review 9.  Cathepsin K inhibitors for osteoporosis and potential off-target effects.

Authors:  Dieter Brömme; Fabien Lecaille
Journal:  Expert Opin Investig Drugs       Date:  2009-05       Impact factor: 6.206

10.  Aging and menopause reprogram osteoclast precursors for aggressive bone resorption.

Authors:  Anaïs Marie Julie Møller; Jean-Marie Delaissé; Jacob Bastholm Olesen; Jonna Skov Madsen; Luisa Matos Canto; Troels Bechmann; Silvia Regina Rogatto; Kent Søe
Journal:  Bone Res       Date:  2020-07-01       Impact factor: 13.567

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.